Pharmacodynamics and pharmacokinetics
Pharmacodynamics
LP receptors of the liver regulate the content of lipoproteins in the blood. Lipoproteins are removed from the circulating blood by interacting with these receptors and cholesterol . The mechanism of action of Lovastatin is explained by the suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, an enzyme with the participation of which cholesterol synthesis occurs. A decrease in the formation of cholesterol in the liver entails a compensatory increase in the number of lipoprotein receptors on the surface of hepatocytes, as a result of which the removal of low-density lipoproteins from the plasma is accelerated and total cholesterol, intermediate-density lipoprotein cholesterol and very low-density lipoprotein cholesterol .
The drug reduces the content of triglycerides and apolipoprotein B , and slightly increases the level of high-density lipoproteins. The therapeutic effect appears after 14 days, and the maximum effect occurs after 6 weeks from the start of treatment, and persists for 1.5 months after discontinuation of the drug. Efficiency does not decrease with long-term use. Lovaststatin is obtained from biocultures of Monascus ruber and Aspergillus terreus.
Pharmacokinetics
Absorbed into the gastrointestinal tract slowly. Absorption is reduced by taking the drug on an empty stomach. Bioavailability is low - 30% of the dose. After 2-4 hours, the maximum concentration in the blood is reached, which decreases and after 24 hours is 10% of the maximum. 95% binds to blood proteins. Clearance of Lovastatin with a single dose is achieved within 2-3 days. Lovastatin is a prodrug and after the first passage through the liver it acquires the active dosage form. Metabolism occurs with the participation of isoenzymes. The half-life is 3 hours. The active substance and its metabolites are excreted through the intestines and kidneys.
Lovastatin tablet 20 mg in container pack No. 10x3
Name
Lovastatin tablet 20 mg in container pack No. 10x3
Description
Tablets are white with a yellowish tint, flat-cylindrical in shape, with a bevel.
Main active ingredient
Lovastatin
Release form
Pills
Dosage
20mg
Pharmacological properties
Pharmacodynamics
Lipid-lowering agent. Lovastatin disrupts the first stage of cholesterol synthesis in the liver - the formation of mevalonic acid. In the body, lovastatin is hydrolyzed to its active form - P-hydroxy acid, which inhibits 3-hydroxy-3-methylglutaryl-CoA reductase and disrupts the conversion of HMG-CoA to mevalonic acid, resulting in decreased cholesterol synthesis and increased catabolism. Lovastatin reduces the blood levels of very low-density lipoproteins, low-density lipoproteins and triglycerides, and moderately increases the levels of high-density lipoproteins. Since the conversion of HMG-CoA to mevalonic acid is an early step in cholesterol synthesis, lovastatin therapy does not lead to the accumulation of toxic sterols. When taking the drug once a day, the duration of action is 24 hours. The effect of lovastatin persists for 4-6 weeks after discontinuation of the course.
Pharmacokinetics
Lovastatin, when taken orally, is slowly and not completely absorbed from the digestive tract (about 30% of the dose taken); when taken on an empty stomach, absorption is reduced by 30%. The maximum plasma concentration of lovastatin is achieved after 2 hours, but then the plasma concentration decreases rapidly and after 24 hours is 10% of the maximum. Lovastatin undergoes active first-pass metabolism followed by excretion of breakdown products in the bile. As a result, the amount of lovastatin entering the systemic circulation is less than 5% of the dose taken. Interindividual variability in bioavailability is approximately 40% for AUC. Both lovastatin and its 0-hydroxy acid metabolite circulate in the general vascular bed in a form bound to plasma proteins (about 95%). A stable steady-state concentration of lovastatin (and its active derivatives) when administered once a day at night (cholesterol is synthesized mainly at night) is achieved on days 2-3 of therapy and is 1.5 times higher than the stable steady-state concentration of lovastatin caused by a single dose. Lovastatin penetrates the BBB and the placental barrier, accumulates in the liver, where it is oxidized to metabolites, some of which remain active. Lovastatin is primarily excreted in bile. About 85% of the dose is excreted in feces and only 10% in urine. A pronounced lipid-lowering effect develops after 2 weeks, the maximum effect occurs within 4-6 weeks. In patients with severe renal impairment (creatinine clearance 10-30 ml/min), after a single dose, lovastatin concentrations were approximately twice as high as in healthy volunteers.
Indications for use
The use of the drug Lovastatin should be an integral part of the treatment of patients with dyslipidemia who are at risk of developing atherosclerotic vascular diseases. Lovastatin should be used in addition to a diet limited in saturated fat and cholesterol, as part of a complex therapy aimed at reducing total cholesterol and LDL-cholesterol to normal levels, in case of ineffectiveness of diet therapy and other non-drug treatment methods. Primary prevention of coronary heart disease. Lovastatin is indicated for patients without clinical signs of cardiovascular disease, with moderately elevated levels of total cholesterol, LDL-cholesterol and reduced HDL levels to reduce the risk of myocardial infarction, unstable angina, and coronary revascularization procedures. Coronary heart disease Lovastatin is prescribed to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of complex therapy aimed at reducing total cholesterol and LDL cholesterol to normal levels. Hypercholesterolemia Lovastatin is prescribed as an adjunct to diet to reduce elevated levels of total cholesterol and LDL cholesterol in patients with primary hypercholesterolemia (types IIa and IIb) when non-drug treatment methods, including diet therapy, are ineffective.
Directions for use and doses
The tablet is taken orally with a sufficient amount of water. Before starting to take lovastatin, the patient must be prescribed a standard cholesterol-lowering diet, which the patient must follow during the entire course of treatment. Doses of lovastatin should be adjusted according to the primary goals of therapy and the patient's response to therapy. The usual initial dose is 20 mg 1 time per day. The drug Lovastatin is taken with dinner. If necessary, dose adjustments can be made at intervals of at least four weeks. The maximum daily dose of lovastatin is 80 mg in 1 or 2 doses (during breakfast and dinner). In patients taking danazol, diltiazem, dronedarone or verapamil, lovastatin therapy should begin at 10 mg and the maximum daily dose should not exceed 20 mg. In patients taking amiodarone, the maximum daily dose of lovastatin should not exceed 40 mg per day. For patients receiving immunosuppressive therapy and patients with severe renal impairment (creatinine clearance less than 30 ml/min), the maximum daily dose of lovastatin is 20 mg. No dose adjustment is required in patients with moderate renal impairment. Patients who require a 20% or greater reduction in LDL cholesterol should begin with 20 mg of lovastatin per day. It is necessary to periodically monitor the level of cholesterol in the blood, if the concentration of total cholesterol decreases to 140 mg/100 ml (3.6 mmol/l) or the concentration of low-density lipoproteins decreases to 75 mg/100 ml (1.94 mmol/l), the dose of lovastatin should be reduced. Lovastatin should be used with caution in patients who drink significant amounts of alcohol and/or have a history of liver disease. If significant pathological changes are detected (an increase in the activity of liver transaminases by more than 3 times compared to the upper limit of normal), the dose of the drug should be reduced or treatment should be discontinued. When using the drug in elderly patients, no dose adjustment is required. If you miss your current dose, Lovastatin should be taken as soon as possible. If it is time to take the next dose, do not double the dose. If you have any doubts or questions, contact your healthcare provider.
Use during pregnancy and lactation
The drug Lovastatin is contraindicated during pregnancy and breastfeeding. The drug Lovastatin should not be used by women planning pregnancy. Safety for use in pregnant women has not been established. If pregnancy occurs, lovastatin should be discontinued immediately. If pregnancy occurs, lovastatin should be discontinued immediately. Lovastatin can be prescribed to women of childbearing age if the possibility of pregnancy has been reliably excluded and the patient has been informed of the potential danger. There is no data on the excretion of lovastatin in breast milk. Given the potential for adverse reactions in breastfeeding infants, women taking lovastatin should discontinue breastfeeding.
Impact on the ability to drive vehicles and operate machinery
Due to the possibility of dizziness, when taking lovastatin (especially at the beginning of treatment), caution should be exercised when driving vehicles and engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Precautionary measures
Effect of lovastatin on the musculoskeletal system Lovastatin, like other HMG-CoA reductase inhibitors, can cause myopathy (muscle pain, soreness and weakness in the muscles with an increase in creatine kinase ten times the upper limit of normal). Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure resulting in myoglobinuria, and, in rare cases, can be fatal. The risk of myopathy increases due to increased inhibitory activity against HMG-CoA reductase in the blood plasma. Before starting therapy, Lovavastatin should be administered with caution to patients with a predisposition to rhabdomyolysis. CPK levels should be determined before starting therapy in the following cases: renal failure; hypothyroidism; hereditary muscle diseases in an individual or family history; previous muscle toxicity due to the use of statins or fibrates; pre-existing liver disease and/or alcohol abuse; elderly patients (over 70 years old) - the need for laboratory tests in this case is also caused by the presence of other predisposition factors to rhabdomyolysis; cases of increased plasma concentrations (for example, cases of interaction and use in special populations, including genetic subpopulations). In the cases listed above, the balance between risk and possible benefit should be assessed, and clinical observation is recommended. If there is a significant increase in CPK concentration (exceeding the upper limit of normal by more than 5 times) at the initial level, treatment should not be started. The risk of developing myopathy/rhabdomyolysis depends on the dose of lovastatin. All patients starting to take lovastatin, or patients whose dose of lovastatin is increased, should be warned of the risk of myopathy and the need to promptly report any unexplained muscle pain, tenderness, or weakness to their prescribers. If confirmed or suspected myopathy is present, treatment with lovastatin should be discontinued immediately. In most cases, when treatment is stopped quickly, muscle symptoms disappear and creatine kinase levels return to normal. Patients starting to take lovastatin or patients for whom the dose of lovastatin is increased should have creatine kinase levels periodically monitored. It should be borne in mind that monitoring the level of creatine kinase does not exclude the possibility of developing myopathy. Many of those patients who developed rhabdomyolysis during lovastatin treatment had complex medical histories, including renal failure, which is usually a consequence of long-term diabetes mellitus. Such patients require more careful monitoring. If CPK levels increase, treatment with lovastatin should be discontinued. Treatment with lovastatin should be temporarily discontinued if the patient has an acute or serious medical condition that predisposes to the development of renal failure secondary to rhabdomyolysis, such as sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine or electrolyte disturbances, or uncontrolled epilepsy. The risk of developing myopathy/rhabdomyolysis increases when lovastatin is co-administered with the following medicinal products: strong CYP3A4 inhibitors: increase plasma levels of lovastatin, which increases the risk of developing myopathy. These drugs include itraconazole, ketoconazole, posaconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, and the antidepressant nefazodone. The combination of these drugs with lovastatin is contraindicated. If therapy with these drugs is necessary, lovastatin should be discontinued during the course of treatment. voriconazole: in vitro, voriconazole has been shown to inhibit the metabolism of lovastatin, increasing the plasma concentration of lovastatin, as a result of which it is recommended to adjust the dose of lovastatin when used concomitantly with voriconazole. Gemfibrozil: Concomitant use of lovastatin with gemfibrozil should be avoided. other lipid-lowering drugs (fibrates or niacin at a dose of > 1 g/day): caution should be exercised when administering fibrates or niacin at lipid-lowering doses (> 1 g/day) with lovastatin, as these drugs may lead to myopathy when monotherapy. The expected benefits and risks of treatment should be carefully weighed when using lovastatin in combination with fibrates or nicotinic acid. cyclosporine: Use of lovastatin with cyclosporine should be avoided. danazol, diltiazem, dronedarone, or verapamil with high-dose lovastatin: In patients taking danazol, diltiazem, dronedarone, or verapamil, lovastatin therapy should begin at 10 mg and the maximum daily dose when coadministered should not exceed 20 mg (see Dosage). application and dose"). Amiodarone: The dose of lovastatin should not exceed 40 mg per day. When taking amiodarone and lovastatin concomitantly, it is possible to use lovastatin at a dose higher than 40 mg per day if the clinical effect outweighs the increased risk of developing myopathy. The risk of developing myopathy/rhabdomyolysis increases when amiodarone is taken concomitantly with high doses of HMG-CoA reductase inhibitors. Colchicine: Cases of myopathy/rhabdomyolysis have been reported with the combined use of lovastatin and colchicine; this combination should be prescribed with caution. ranolazine: Fusidic acid: As with other statins, muscle disturbances, including rhabdomyolysis, have been reported during post-marketing surveillance with concomitant use of atorvastatin and fusidic acid. Very rare cases of immune-mediated necrotizing myopathy have been reported during and after statin therapy. Clinical manifestations were characterized by proximal muscle weakness and increased serum creatine kinase activity, which persisted after cessation of statin therapy. Effect of lovastatin on the liver It is necessary to monitor the level of activity of transaminases and other liver enzymes in the blood serum before starting statin therapy and as clinically indicated during use. In the presence of serious liver damage with clinical symptoms and/or hyperbilirubinemia, jaundice appearing during administration, the use of statins should be discontinued. Unless another cause of serious liver damage has been identified, statin use should not be restarted. Statins are prescribed with caution in case of a history of liver disease, chronic alcoholism, organ transplantation, concomitant immunosuppressive therapy, chronic renal failure, urgent surgical procedures (including dental). Interstitial lung diseases There have been reports of very rare cases of interstitial lung disease developing when taking statins, especially with long-term therapy. If symptoms of interstitial lung disease appear, such as respiratory distress, shortness of breath, nonproductive cough, deterioration in general condition (fatigue, weight loss, fever), statin therapy should be discontinued. Diabetes Statins increase blood glucose levels and, in patients at high risk of developing diabetes, may cause elevated blood sugar levels that require appropriate treatment. However, the benefits of statins in reducing the risk of cardiovascular disease outweigh the small increase in the risk of diabetes, so statin use should not be stopped. Periodic monitoring of biochemical and clinical glycemia is necessary in patients at risk (fasting glucose 5.6-6.9 mmol/l, body mass index > 30 kg/m2, increased triglyceride levels, hypertension), according to current recommendations. Statins should be used with caution in patients with rare hereditary diseases: congenital galactosemia, lactase deficiency, glucose/galactose malabsorption syndrome, since the drug contains lactose. You should tell your doctor immediately if you have any unexplained muscle pain, tenderness, or weakness.
Interaction with other drugs
It is necessary to inform doctors prescribing a new drug that you are taking the drug Lovastatin. Interaction with inhibitors of the CYP3A4 isoenzyme Lovastatin is metabolized by the CYP3A4 isoenzyme, but does not have inhibitory activity against this isoenzyme, therefore lovastatin cannot cause an increase in plasma concentrations of other drugs metabolized by CYP3A4. Co-administration of strong CYP3A4 inhibitors (itraconazole, ketoconazole, posaconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone and erythromycin, cyclosporine) with lovastatin is contraindicated due to an increased risk of myopathy due to a decrease in the rate of elimination of lovastatin. In vitro, voriconazole inhibits the metabolism of lovastatin. When used concomitantly, it is recommended to adjust the dose of lovastatin to reduce the risk of developing myopathy/rhabdomyolysis. Interaction with lipid-lowering drugs that can cause myopathy during monotherapy The risk of developing myopathy increases with the use of lipid-lowering drugs that are not strong inhibitors of CYP3A4 (gemfibrozil, other fibrates, nicotinic acid (> 1 g / day), but which can lead to myopathy in monotherapy. Danazol, diltiazem, dronedarone or verapamil: the risk of myopathy/rhabdomyolysis increases with simultaneous use of danazol, diltiazem, especially with higher doses of lovastatin. The dose of lovastatin should not exceed 20 mg per day when taken together with danazol, diltiazem. Amiodarone: The risk of myopathy/rhabdomyolysis increases when amiodarone or verapamil is used concomitantly with other statins (HMG-CoA reductase inhibitors).In patients taking amiodarone, the initial dose of lovastatin is 10 mg, and the maximum daily dose should not exceed 20 mg when taken together ( see section "Method of administration and dosage"). Coumarin anticoagulants: For patients taking anticoagulants, it is recommended that the prothrombin time be determined before starting lovastatin. It is often sufficient to determine the prothrombin time at the beginning of therapy to ensure that it does not change significantly during therapy. Once a stable level of prothrombin time is achieved, its further monitoring should be carried out at intervals recommended for patients receiving anticoagulant therapy. When changing the dosage of lovastatin, prothrombin time should also be monitored according to the above scheme. Lovastatin therapy does not cause changes in prothrombin time and the risk of bleeding in patients not taking anticoagulants. Colchicine: Cases of myopathy, including rhabdomyolysis, have been reported when colchicine is used concomitantly with lovastatin. Ranolazine: Concomitant use of ranolazine and lovastatin increases the risk of myopathy/rhabdomyolysis. Propranolol: There were no clinically significant pharmacokinetic or pharmacodynamic interactions when single doses of lovastatin and propranolol were co-administered in healthy volunteers. Digoxin: When lovastatin and digoxin were taken concomitantly in patients with hypercholesterolemia, the concentration of digoxin in plasma did not change. Oral hypoglycemic medicinal products: In pharmacokinetic studies in patients with hypercholesterolemic non-insulin-dependent diabetes, lovastatin did not interact with glipizide or chlorpropamide. Endocrine function: Patients with endocrine dysfunction or patients taking drugs that affect the activity of endogenous steroid hormones when co-administered with lovastatin require medical supervision. Other Interactions Concomitant use of grapefruit juice and lovastatin may result in increased plasma concentrations of lovastatin, so patients taking lovastatin should avoid consuming grapefruit juice. Other concomitant therapy With the combined use of lovastatin and ACE inhibitors, 0-blockers, calcium antagonists (except verapamil), diuretics, non-steroidal anti-inflammatory drugs, clinically significant interactions have not been identified.
Contraindications
Hypersensitivity to any of the components of the drug. Acute liver diseases, constant increase in the activity of liver transaminases of unknown origin, cholestasis. Pregnancy, breastfeeding, age up to 18 years. Muscle diseases (myopathy). Co-administration of lovastatin with: potent inhibitors of the CYP3A4 enzyme (for example, itraconazole, ketoconazole, posaconazole, HIV protease inhibitors, erythromycin, clarithromycin, telithromycin, nefazodone, boceprevir, telaprevir), mifebradil (for details see the section "Interaction with other drugs" ).
Compound
Each tablet contains: active ingredient: lovastatin - 20 mg; excipients: corn starch, microcrystalline cellulose, colloidal anhydrous silicon dioxide, magnesium stearate, butylated hydroxyanisole E 320, lactose monohydrate.
Overdose
Symptoms: overdose is accompanied by increased side effects. Treatment: symptomatic therapy, monitoring liver function. A specific antidote is unknown.
Side effect
The frequency of adverse reactions is established using the following gradation: very often - 1/10 or more; often from 1/100 to 1/10; infrequently - from 1/1,000 to 1/100; rarely - from 1/10,000 to 1/1,000); very rare - less than 1/10,000, unknown - cannot be estimated based on available data). Nervous system disorders: often - dizziness, headache; infrequently - insomnia, sleep disturbances, paresthesia; unknown - peripheral neuropathy, memory impairment. Violations of the organ of vision: often - blurred vision; uncommon: eye irritation. Disorders of the respiratory system, chest and mediastinal organs: uncommon - chest pain. Disorders of the digestive system: often - abdominal pain, constipation, diarrhea, dyspepsia, flatulence, nausea; uncommon - heartburn, vomiting, dry mouth, change in taste; rarely - stomatitis, pancreatitis. Disorders of the skin and subcutaneous tissue: often - rash; infrequently - itching. Disorders of the musculoskeletal system and connective tissue: often - involuntary muscle contractions, muscle pain; uncommon - pain in the lower extremities, shoulder pain, joint pain; rarely - myopathy and rhabdomyolysis with or without acute liver failure; frequency unknown - immune-mediated necrotizing myopathy. Reproductive system disorders: rarely - decreased libido. Endocrine system disorders: rarely - gynecomastia. Mental disorders: unknown - anxiety. Immune system disorders: rarely - urticaria, Quincke's edema, toxic epidermal necrolysis, anaphylactic shock, lupus erythematous syndrome, polymyalgia rheumatica, arthritis, photosensitivity, fever, chills, hot flashes, Stevens-Johnson syndrome. Metabolic disorders: unknown - anorexia. Disorders of the hepatobiliary system: unknown - hepatitis, cholestatic jaundice. General disorders: often - weakness; infrequently - fatigue, hair loss; rarely - swelling. Impact on the results of laboratory and instrumental studies: rarely - increased serum transaminases, alkaline phosphatase and bilirubin, increased creatine kinase. The following adverse events have been observed with certain statins: sexual dysfunction, depression, rare cases of interstitial lung disease, especially with long-term therapy, diabetes mellitus. If any adverse reactions occur, including those not listed in this instruction, you must stop taking the medicine and consult a doctor.
Storage conditions
In a place protected from moisture and light at a temperature not exceeding 25 °C. Keep out of the reach of children.
Side effects
- heartburn , nausea, flatulence , constipation or diarrhea ; very rarely - taste perversion, hepatitis , biliary cholestasis , cholestatic jaundice ;
- headache, dizziness; sleep disorders, insomnia , general weakness, anxiety, paresthesia ;
- myalgia and muscle cramps, myositis ; in patients taking Cyclosporine , Nicotinic acid or Gemfibrozil , there is a risk of developing rhabdomyolysis ;
- hemolytic anemia , thrombocytopenia ;
- optic atrophy , cataracts ;
- increased activity of liver transaminases, creatine phosphokinase activity; very rarely alkaline phosphatase and bilirubin.
- rash, itching, angioedema , urticaria , arthralgia ;
- very rarely, decreased potency and alopecia .
Lovastatin, instructions for use (Method and dosage)
Tablets are taken orally 1 time per day during dinner. For hyperlipidemia - from 10 to 80 mg once, depending on the severity of hyperlipidemia. Treatment begins with a small dose, then gradually increases it. The maximum daily dose of 80 mg can be taken in one or two doses (morning and evening). Dose selection is carried out at intervals of 4 weeks.
For coronary atherosclerosis, the dose is 20–40 mg. If ineffective, increase to 60–80 mg. When taking fibrates or nicotinic acid , the dose of Lovastatin should not exceed 20 mg per day.
Overdose
If the recommended doses of the drug are exceeded, an overdose cannot be ruled out. Treatment is symptomatic, aimed at alleviating the current condition. Absorbents, enterosorbents, and diuretics may be prescribed. The patient should drink plenty of fluids.
If the recommended dosage is exceeded and side symptoms develop, drugs from the group of enterosorbents are prescribed
Important! The hemodialysis procedure is effective only in severe cases of poisoning.
Interaction
Taking with Nicotinic acid , Erythromycin , Clarithromycin , Cyclosporine , antifungal drugs ( Ketoconazole , Itraconazole ), Ritonavir , Nefazodone leads to an increase in the concentration of the drug, the risk of developing myopathy and destruction of muscle tissue.
Simultaneous intake of large amounts of grapefruit juice, Gemfibrozil , Fenofibrate also carries a risk of developing myopathies.
Co-administration of Warfarin increases the risk of bleeding.
Cholestyramine reduces the bioavailability of the drug, so the time between taking these drugs should be 2-4 hours.
Lovastatin analogues
Level 4 ATX code matches:
Akorta
Atomax
Lipitor
Pravastatin
Simvastol
Owencore
Simgal
Tulip
Liptonorm
Rozulip
Zokor
Rosart
Tevastor
Atorvastatin
Liprimar
Simvastatin
Atoris
Basilip
Rosecard
Roxera
Apexstatin , Cardiostatin , Vero-Lovastatin , Choletar , Mevacor , Lovacor , Lovasterol , Mevinacor , Pravastatin , Iinvastin , Fluvastatin .
Reviews of Lovastatin
Lipid-lowering drugs are used in complex treatment and for the prevention of atherosclerosis and its complications. Their main effect is to reduce the content of atherogenic lipoproteins in the blood. Representatives of the statin group (in order of increasing effect) are: Lovastatin , Simvastatin , Fluvastatin , Pravastatin , Atorvastatin and Rosuvastatin . Often, as the main effect increases, the risk of side effects also increases.
Extensive experience has been accumulated in the clinical use of Lovastatin, which is the safest drug and is well tolerated during long-term treatment. According to patient reviews, side effects appeared quite rarely: flatulence , diarrhea or constipation , abdominal pain, insomnia, muscle pain. As a rule, these reactions disappeared after 2 weeks of taking the drug or after reducing the dose. If the levels of AST and ALT increased after a month, the tests were monitored and the dose of the drug was reduced. After 1.5-2 months from the start of treatment, a control determination of lipid levels was carried out and positive dynamics were noted in the tests.
Indications for use
Lovastatin is used to diagnose the following conditions:
- hypercholesterolemia (primary type IIa/IIb, combined)
- hypertriglyceridemia;
- hyperlipoproteinemia;
- atherosclerosis.
Cholesterol synthesis and the effect of statins on the level of the substance in the body
The medication is used in patients with diabetes to prevent the development of serious complications. Treatment with Lovestatin can be combined with antihyperglycemic drugs. Taking a lipid-lowering drug is possible to prevent the development of pathologies of the heart and blood vessels. This is especially true for possible relapses of heart attack, stroke and others. In this case, it is prescribed in combination with cardiac medications.
No ads 1
